期刊文献+

艾司西酞普兰与氟西汀门诊治疗抑郁发作的临床研究 被引量:1

Clinical study of Escitalopram and Fluoxetine in the treatment of depression in outpatient
下载PDF
导出
摘要 目的:探讨艾司西酞普兰门诊治疗抑郁发作的疗效及安全性。方法:将门诊符合CCMD-3抑郁发作诊断标准的患者100例随机分成艾司西肽普兰组及氟西汀组各50例,艾司西酞普兰最大剂量30mg/d,氟西汀最大剂量60mg/d,采用汉密尔顿抑郁量表(HAMD)减分率评定疗效,用TESS评定不良反应,观察时间为6周,结果:艾司西酞普兰组有效率70%,治愈率44%;氟西汀组有效率64%,治愈率36%。两组比较无显著性差异(P>0.05)。艾司西酞普兰主要不良反应为食欲减退(10%)、恶心(8%)、头晕、(6%)、口干(2%),与氟西汀比较无显著性差异。结论:艾司西酞普兰门诊治疗抑郁发作的疗效确切、安全,且起效快、副反应小,经济上大多能承受,可以广泛应用。 Objective: To discuss the efficacy and safety of Escitalopram in the treatment of depression in outpatient. Methods: 100 outpatients who met the Chinese of Medical Disorders( CCMD -3 ) criteria for depression were randomly divided into Escitalopram group (50 cases)and Fluoxetine group(50 cases) , Escitalopram maximum dose of 30mg/d, and Fluoxetine maximum dose of 60mg/d. HAMD was used to assess efficacy, and TESS was used to assess adverse reactions,observation time of six weeks. Results:The effective rate and cure rate of Escitalopram were 70% and 44% respectively, Fluoxetine were 64% and36% ; the two ~oups were not significantly different ( P 〉 0.05 ). Anorexia ( 10% ), nausea ( 8% ), dry mouth ( 2% ), dizziness (6%) were the most frequently reported adverse events in escitalopram group and fluoxetine group, there were not significantly different. Conclusion:The curative effect of Escitalopram outpatient treatment of depressive episode is accurate, and safe, fast onset of action, small adverse reaction, can be widely applied.
出处 《中国民康医学》 2013年第14期17-18,共2页 Medical Journal of Chinese People’s Health
关键词 艾司西酞普兰 氟西汀 抑郁发作 Escitalopram Fluoxetine Depression
  • 相关文献

参考文献2

  • 1司天梅,舒良.关于新抗抑郁药艾司西酞普兰[J].临床精神医学杂志,2007,17(1):68-69. 被引量:124
  • 2Colonna L,Andersen HF, Reines EH. A randomized ,double- blind ,24 - week study of escitalopram ( 10rag/day ) versus citalopram ( 20mg/ day) in primary care patients with major depressive disorder[ J ]. Curr Med Res Opin ,2005 ,21 (10) : 1659 - 1668..

二级参考文献14

  • 1Owens MJ,Knight DL,Nemeroff CB.Second generation SSRIs:human monoamine transporter binding profile of escitalopram and R-fluoxetine[J].Biol Psychiatry,2001,50:345-350.
  • 2Chen FH,Larsen MB,Sanchezc,et al.The S-enantiomer of R,S-citalopram,increases inhibitor binding to the human serotonin transporter by an allosteric mechanism.Comparison with other serotonin transporter inhibitors[J].Eur Neuropsychopharmacology,2005,15:193-198.
  • 3Mork A,Kreilgaard M,Sanchez C.The R-enantiomer of citalopram counteracts escitalopram-induced increase in extracellular 5-HT in the frontal cortex of freely moving rats[J].Neuropharmacology,2003,45:167-173.
  • 4Sanchez C.R-citalopram attenuates anxiolytic effects of escitalopram in a rat ultrasonic vocalization model[J].Eur J Pharmacol,2003,464:155-158.
  • 5Sanchez C,Gruca P,Papp M.R-citalopram counteracts the antidepressant-like effect of escitalopram in a rat chronic mild stress model of depression[J].Behav Pharmacol,2003,14:465-470.
  • 6Plenge P,Mellerup ET,Laursen H.Affinity modulation of[^3H]imipramine,[^3H]paroxetine and[^3H]citalopram binding to the 5-HT transporter from brain and platelets[J].Eur J Pharmacol,1991,206:243-250.
  • 7Fava M,Davidson KG.Definition and epidemiology of treatment resistant depression[J].Psychiatr Clin North Am,1996,19:179-200.
  • 8Thase ME.The Concept of Remission:validity and limitations[J].JClin Psychiatry,2006,67:478-481.
  • 9Thase ME.Evaluating antidepressant therapies:Remission as the optimal outcome[J].J Clin Psychiatry,2003,64(Suppl 13):18-25.
  • 10Murdoch D,Keam SJ.Escitalopram:a review of its use in the management of major depressive disorder[J].Drugs,2005,65:2379-2404.

共引文献123

同被引文献12

引证文献1

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部